To learn more about Selective Internal Radiation Therapy (SIRT) for treating liver cancer and the unique benefits of our products, visit our patient information website.
Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.
The Quirem team will attend CIRSE in Barcelona from September 7-11 2019.
SIRT in three steps
Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to improve patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in three simple steps:
News and events
Deventer, August 7, 2019 – Today a first clinical QuiremScout® patient procedure took place with radioactive holmium-166 microspheres that were activated at the NRG reactor in Petten, the Netherlands. QuiremScout® is an innovative product for
On July 31, Quirem Medical received with great pleasure Mr. Zhang Guosheng – the Economic & Commercial Counsellor from the Embassy of the People’s Republic of China. The CEO of Quirem Medical, Jan Sigger, and the
McMaster University and Quirem Medical announce the first clinical case using the McMaster Nuclear Reactor Deventer (The Netherlands), Hamilton (Canada), 6th of June 2019 McMaster University and Quirem Medical announce the first clinical case using
What our customers say